RapamycinFungusV1, Main, Exploration, bibRecord, 001021

Large FK506-binding proteins shape the pharmacology of rapamycin.

Identifieur interne : 001021 ( Main/Exploration ); précédent : 001020; suivant : 001022

Large FK506-binding proteins shape the pharmacology of rapamycin.

Auteurs : Andreas M. M Rz [Allemagne] ; Anne-Katrin Fabian ; Christian Kozany ; Andreas Bracher ; Felix Hausch

Source :

Molecular and cellular biology [ 1098-5549 ] ; 2013.

RBID : pubmed:23358420

Descripteurs français

KwdFr :
- Cellules HEK293 (MeSH), Cellules HeLa (MeSH), Humains (MeSH), Immunosuppresseurs (pharmacologie), Liaison aux protéines (MeSH), Lignée cellulaire (MeSH), Lignée cellulaire tumorale (MeSH), Phosphorylation (effets des médicaments et des substances chimiques), Protéines de liaison au tacrolimus (composition chimique), Protéines de liaison au tacrolimus (métabolisme), Protéines proto-oncogènes c-akt (métabolisme), Saccharomyces cerevisiae (métabolisme), Sirolimus (composition chimique), Sirolimus (pharmacologie), Sérine-thréonine kinases TOR (antagonistes et inhibiteurs), Sérine-thréonine kinases TOR (métabolisme), Tacrolimus (métabolisme), Tacrolimus (pharmacologie).
MESH :
- antagonistes et inhibiteurs : Sérine-thréonine kinases TOR.
- composition chimique : Protéines de liaison au tacrolimus, Sirolimus.
- effets des médicaments et des substances chimiques : Phosphorylation.
- métabolisme : Protéines de liaison au tacrolimus, Protéines proto-oncogènes c-akt, Saccharomyces cerevisiae, Sérine-thréonine kinases TOR, Tacrolimus.
- pharmacologie : Immunosuppresseurs, Sirolimus, Tacrolimus.
- Cellules HEK293, Cellules HeLa, Humains, Liaison aux protéines, Lignée cellulaire, Lignée cellulaire tumorale.

English descriptors

KwdEn :
- Cell Line (MeSH), Cell Line, Tumor (MeSH), HEK293 Cells (MeSH), HeLa Cells (MeSH), Humans (MeSH), Immunosuppressive Agents (pharmacology), Phosphorylation (drug effects), Protein Binding (MeSH), Proto-Oncogene Proteins c-akt (metabolism), Saccharomyces cerevisiae (metabolism), Sirolimus (chemistry), Sirolimus (pharmacology), TOR Serine-Threonine Kinases (antagonists & inhibitors), TOR Serine-Threonine Kinases (metabolism), Tacrolimus (metabolism), Tacrolimus (pharmacology), Tacrolimus Binding Proteins (chemistry), Tacrolimus Binding Proteins (metabolism).
MESH :
- chemical , antagonists & inhibitors : TOR Serine-Threonine Kinases.
- chemical , chemistry : Sirolimus, Tacrolimus Binding Proteins.
- chemical , metabolism : Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases, Tacrolimus, Tacrolimus Binding Proteins.
- chemical , pharmacology : Immunosuppressive Agents, Sirolimus, Tacrolimus.
- drug effects : Phosphorylation.
- metabolism : Saccharomyces cerevisiae.
- Cell Line, Cell Line, Tumor, HEK293 Cells, HeLa Cells, Humans, Protein Binding.

Abstract

The immunosuppressant and anticancer drug rapamycin works by inducing inhibitory protein complexes with the kinase mTOR, an important regulator of growth and proliferation. The obligatory accessory partner of rapamycin is believed to be FK506-binding protein 12 (FKBP12). Here we show that rapamycin complexes of larger FKBP family members can tightly bind to mTOR and potently inhibit its kinase activity. Cocrystal structures with FKBP51 and FKBP52 reveal the modified molecular binding mode of these alternative ternary complexes in detail. In cellular model systems, FKBP12 can be functionally replaced by larger FKBPs. When the rapamycin dosage is limiting, mTOR inhibition of S6K phosphorylation can be enhanced by FKBP51 overexpression in mammalian cells, whereas FKBP12 is dispensable. FKBP51 could also enable the rapamycin-induced hyperphosphorylation of Akt, which depended on higher FKBP levels than rapamycin-induced inhibition of S6K phosphorylation. These insights provide a mechanistic rationale for preferential mTOR inhibition in specific cell or tissue types by engaging specific FKBP homologs.

DOI: 10.1128/MCB.00678-12
PubMed: 23358420
PubMed Central: PMC3624267

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001061
to stream Main, to step Curation: 001061

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Large FK506-binding proteins shape the pharmacology of rapamycin.</title>
<author><name sortKey="M Rz, Andreas M" sort="M Rz, Andreas M" uniqKey="M Rz A" first="Andreas M" last="M Rz">Andreas M. M Rz</name>
<affiliation wicri:level="3"><nlm:affiliation>Max Planck Institute of Psychiatry, Department of Chemical Genomics, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Max Planck Institute of Psychiatry, Department of Chemical Genomics, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fabian, Anne Katrin" sort="Fabian, Anne Katrin" uniqKey="Fabian A" first="Anne-Katrin" last="Fabian">Anne-Katrin Fabian</name>
</author>
<author><name sortKey="Kozany, Christian" sort="Kozany, Christian" uniqKey="Kozany C" first="Christian" last="Kozany">Christian Kozany</name>
</author>
<author><name sortKey="Bracher, Andreas" sort="Bracher, Andreas" uniqKey="Bracher A" first="Andreas" last="Bracher">Andreas Bracher</name>
</author>
<author><name sortKey="Hausch, Felix" sort="Hausch, Felix" uniqKey="Hausch F" first="Felix" last="Hausch">Felix Hausch</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23358420</idno>
<idno type="pmid">23358420</idno>
<idno type="doi">10.1128/MCB.00678-12</idno>
<idno type="pmc">PMC3624267</idno>
<idno type="wicri:Area/Main/Corpus">001061</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001061</idno>
<idno type="wicri:Area/Main/Curation">001061</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001061</idno>
<idno type="wicri:Area/Main/Exploration">001061</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Large FK506-binding proteins shape the pharmacology of rapamycin.</title>
<author><name sortKey="M Rz, Andreas M" sort="M Rz, Andreas M" uniqKey="M Rz A" first="Andreas M" last="M Rz">Andreas M. M Rz</name>
<affiliation wicri:level="3"><nlm:affiliation>Max Planck Institute of Psychiatry, Department of Chemical Genomics, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Max Planck Institute of Psychiatry, Department of Chemical Genomics, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fabian, Anne Katrin" sort="Fabian, Anne Katrin" uniqKey="Fabian A" first="Anne-Katrin" last="Fabian">Anne-Katrin Fabian</name>
</author>
<author><name sortKey="Kozany, Christian" sort="Kozany, Christian" uniqKey="Kozany C" first="Christian" last="Kozany">Christian Kozany</name>
</author>
<author><name sortKey="Bracher, Andreas" sort="Bracher, Andreas" uniqKey="Bracher A" first="Andreas" last="Bracher">Andreas Bracher</name>
</author>
<author><name sortKey="Hausch, Felix" sort="Hausch, Felix" uniqKey="Hausch F" first="Felix" last="Hausch">Felix Hausch</name>
</author>
</analytic>
<series><title level="j">Molecular and cellular biology</title>
<idno type="eISSN">1098-5549</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cell Line (MeSH)</term>
<term>Cell Line, Tumor (MeSH)</term>
<term>HEK293 Cells (MeSH)</term>
<term>HeLa Cells (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunosuppressive Agents (pharmacology)</term>
<term>Phosphorylation (drug effects)</term>
<term>Protein Binding (MeSH)</term>
<term>Proto-Oncogene Proteins c-akt (metabolism)</term>
<term>Saccharomyces cerevisiae (metabolism)</term>
<term>Sirolimus (chemistry)</term>
<term>Sirolimus (pharmacology)</term>
<term>TOR Serine-Threonine Kinases (antagonists & inhibitors)</term>
<term>TOR Serine-Threonine Kinases (metabolism)</term>
<term>Tacrolimus (metabolism)</term>
<term>Tacrolimus (pharmacology)</term>
<term>Tacrolimus Binding Proteins (chemistry)</term>
<term>Tacrolimus Binding Proteins (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Cellules HEK293 (MeSH)</term>
<term>Cellules HeLa (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Immunosuppresseurs (pharmacologie)</term>
<term>Liaison aux protéines (MeSH)</term>
<term>Lignée cellulaire (MeSH)</term>
<term>Lignée cellulaire tumorale (MeSH)</term>
<term>Phosphorylation (effets des médicaments et des substances chimiques)</term>
<term>Protéines de liaison au tacrolimus (composition chimique)</term>
<term>Protéines de liaison au tacrolimus (métabolisme)</term>
<term>Protéines proto-oncogènes c-akt (métabolisme)</term>
<term>Saccharomyces cerevisiae (métabolisme)</term>
<term>Sirolimus (composition chimique)</term>
<term>Sirolimus (pharmacologie)</term>
<term>Sérine-thréonine kinases TOR (antagonistes et inhibiteurs)</term>
<term>Sérine-thréonine kinases TOR (métabolisme)</term>
<term>Tacrolimus (métabolisme)</term>
<term>Tacrolimus (pharmacologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>TOR Serine-Threonine Kinases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Sirolimus</term>
<term>Tacrolimus Binding Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Proto-Oncogene Proteins c-akt</term>
<term>TOR Serine-Threonine Kinases</term>
<term>Tacrolimus</term>
<term>Tacrolimus Binding Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Immunosuppressive Agents</term>
<term>Sirolimus</term>
<term>Tacrolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sérine-thréonine kinases TOR</term>
</keywords>
<keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Protéines de liaison au tacrolimus</term>
<term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Phosphorylation</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Phosphorylation</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Saccharomyces cerevisiae</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Protéines de liaison au tacrolimus</term>
<term>Protéines proto-oncogènes c-akt</term>
<term>Saccharomyces cerevisiae</term>
<term>Sérine-thréonine kinases TOR</term>
<term>Tacrolimus</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Immunosuppresseurs</term>
<term>Sirolimus</term>
<term>Tacrolimus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cell Line</term>
<term>Cell Line, Tumor</term>
<term>HEK293 Cells</term>
<term>HeLa Cells</term>
<term>Humans</term>
<term>Protein Binding</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Cellules HEK293</term>
<term>Cellules HeLa</term>
<term>Humains</term>
<term>Liaison aux protéines</term>
<term>Lignée cellulaire</term>
<term>Lignée cellulaire tumorale</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The immunosuppressant and anticancer drug rapamycin works by inducing inhibitory protein complexes with the kinase mTOR, an important regulator of growth and proliferation. The obligatory accessory partner of rapamycin is believed to be FK506-binding protein 12 (FKBP12). Here we show that rapamycin complexes of larger FKBP family members can tightly bind to mTOR and potently inhibit its kinase activity. Cocrystal structures with FKBP51 and FKBP52 reveal the modified molecular binding mode of these alternative ternary complexes in detail. In cellular model systems, FKBP12 can be functionally replaced by larger FKBPs. When the rapamycin dosage is limiting, mTOR inhibition of S6K phosphorylation can be enhanced by FKBP51 overexpression in mammalian cells, whereas FKBP12 is dispensable. FKBP51 could also enable the rapamycin-induced hyperphosphorylation of Akt, which depended on higher FKBP levels than rapamycin-induced inhibition of S6K phosphorylation. These insights provide a mechanistic rationale for preferential mTOR inhibition in specific cell or tissue types by engaging specific FKBP homologs.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23358420</PMID>
<DateCompleted><Year>2013</Year>
<Month>07</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5549</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>33</Volume>
<Issue>7</Issue>
<PubDate><Year>2013</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Molecular and cellular biology</Title>
<ISOAbbreviation>Mol Cell Biol</ISOAbbreviation>
</Journal>
<ArticleTitle>Large FK506-binding proteins shape the pharmacology of rapamycin.</ArticleTitle>
<Pagination><MedlinePgn>1357-67</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/MCB.00678-12</ELocationID>
<Abstract><AbstractText>The immunosuppressant and anticancer drug rapamycin works by inducing inhibitory protein complexes with the kinase mTOR, an important regulator of growth and proliferation. The obligatory accessory partner of rapamycin is believed to be FK506-binding protein 12 (FKBP12). Here we show that rapamycin complexes of larger FKBP family members can tightly bind to mTOR and potently inhibit its kinase activity. Cocrystal structures with FKBP51 and FKBP52 reveal the modified molecular binding mode of these alternative ternary complexes in detail. In cellular model systems, FKBP12 can be functionally replaced by larger FKBPs. When the rapamycin dosage is limiting, mTOR inhibition of S6K phosphorylation can be enhanced by FKBP51 overexpression in mammalian cells, whereas FKBP12 is dispensable. FKBP51 could also enable the rapamycin-induced hyperphosphorylation of Akt, which depended on higher FKBP levels than rapamycin-induced inhibition of S6K phosphorylation. These insights provide a mechanistic rationale for preferential mTOR inhibition in specific cell or tissue types by engaging specific FKBP homologs.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>März</LastName>
<ForeName>Andreas M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo><Affiliation>Max Planck Institute of Psychiatry, Department of Chemical Genomics, Munich, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fabian</LastName>
<ForeName>Anne-Katrin</ForeName>
<Initials>AK</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kozany</LastName>
<ForeName>Christian</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bracher</LastName>
<ForeName>Andreas</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hausch</LastName>
<ForeName>Felix</ForeName>
<Initials>F</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>01</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mol Cell Biol</MedlineTA>
<NlmUniqueID>8109087</NlmUniqueID>
<ISSNLinking>0270-7306</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 5.2.1.-</RegistryNumber>
<NameOfSubstance UI="D022021">Tacrolimus Binding Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 5.2.1.-</RegistryNumber>
<NameOfSubstance UI="C403485">tacrolimus binding protein 4</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 5.2.1.8</RegistryNumber>
<NameOfSubstance UI="C403486">tacrolimus binding protein 5</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>WM0HAQ4WNM</RegistryNumber>
<NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012441" MajorTopicYN="N">Saccharomyces cerevisiae</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D022021" MajorTopicYN="N">Tacrolimus Binding Proteins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>1</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>1</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2013</Year>
<Month>7</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">23358420</ArticleId>
<ArticleId IdType="pii">MCB.00678-12</ArticleId>
<ArticleId IdType="doi">10.1128/MCB.00678-12</ArticleId>
<ArticleId IdType="pmc">PMC3624267</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Mol Cell. 2010 Jun 11;38(5):768-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20542007</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2009 Sep 8;16(3):259-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19732725</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochemistry. 2006 Dec 26;45(51):15776-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17176100</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1991 Aug 23;253(5022):905-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1715094</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20383002</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2009 Mar 20;284(12):8023-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19150980</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Med Chem. 2011;18(35):5355-79</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22087830</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1995 May 23;92(11):4947-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7539137</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell Biol. 1999 Jun;19(6):4101-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10330150</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Methods Enzymol. 2009;452:165-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19200882</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Crystallogr D Biol Crystallogr. 2006 Jan;62(Pt 1):72-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16369096</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2011 Jun 10;332(6035):1322-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21659605</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cell. 2006 Apr 21;22(2):159-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16603397</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2012 May 10;55(9):4123-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22455398</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eukaryot Cell. 2012 Mar;11(3):270-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22210828</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1999 Feb 12;274(7):4266-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9933627</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2005 Feb 18;307(5712):1098-101</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15718470</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Genomics. 2006;7:244</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16995943</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem J. 1993 Sep 1;294 ( Pt 2):511-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8373365</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 1997 Mar 17;232(2):437-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9125197</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Chem. 2012 May 10;55(9):4114-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22455444</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Pharmacol. 2005 Feb 10;509(1):11-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15713424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Crystallogr D Biol Crystallogr. 1999 Apr;55(Pt 4):736-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10089303</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chembiochem. 2009 May 25;10(8):1402-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19418507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Biol. 2002 Apr 16;12(8):632-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11967149</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FEBS Lett. 2009 Mar 18;583(6):965-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19222999</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21460441</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neoplasia. 2008 Mar;10(3):235-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18320068</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21157483</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15299926</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6062-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15075390</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Kidney Int. 2001 Jan;59(1):3-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11135052</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2007 Nov 9;318(5852):977-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17991864</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7769-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7689229</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Struct Biol. 1999 May;6(5):458-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10331874</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Soc Trans. 2011 Apr;39(2):431-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21428914</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2009 Jul 16;460(7253):392-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19587680</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antibiot (Tokyo). 1975 Oct;28(10):721-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1102508</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Coll Cardiol. 2004 Oct 6;44(7):1386-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15464317</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2012 Apr 13;149(2):274-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22500797</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Neurosci. 2011 Aug;12(8):437-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21772323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1995 Nov 3;270(44):26511-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7592869</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2011 Jun 10;332(6035):1317-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21659604</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2012 Mar 30;335(6076):1638-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22461615</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2001 Nov;45(11):3162-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11600372</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neuron. 2008 Dec 10;60(5):832-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19081378</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Methods Enzymol. 2008;438:307-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18413257</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2011 Nov;10(11):868-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22037041</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neurosci. 2010 Feb 17;30(7):2454-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20164329</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Biol. 2004 Jul 27;14(14):1296-302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15268862</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Chem Soc. 2005 Apr 6;127(13):4715-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15796538</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Cycle. 2009 Feb 15;8(4):567-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19197153</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Genes Dev. 2010 Sep 15;24(18):2019-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20801936</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2011 Feb 25;286(8):6510-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21177869</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14169-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14605212</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 1993 Dec 20;234(4):946-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8263940</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Cell Biol. 2011 Dec;23(6):707-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21925855</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
</country>
<region><li>Bavière</li>
<li>District de Haute-Bavière</li>
</region>
<settlement><li>Munich</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Bracher, Andreas" sort="Bracher, Andreas" uniqKey="Bracher A" first="Andreas" last="Bracher">Andreas Bracher</name>
<name sortKey="Fabian, Anne Katrin" sort="Fabian, Anne Katrin" uniqKey="Fabian A" first="Anne-Katrin" last="Fabian">Anne-Katrin Fabian</name>
<name sortKey="Hausch, Felix" sort="Hausch, Felix" uniqKey="Hausch F" first="Felix" last="Hausch">Felix Hausch</name>
<name sortKey="Kozany, Christian" sort="Kozany, Christian" uniqKey="Kozany C" first="Christian" last="Kozany">Christian Kozany</name>
</noCountry>
<country name="Allemagne"><region name="Bavière"><name sortKey="M Rz, Andreas M" sort="M Rz, Andreas M" uniqKey="M Rz A" first="Andreas M" last="M Rz">Andreas M. M Rz</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001021 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001021 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:23358420
   |texte=   Large FK506-binding proteins shape the pharmacology of rapamycin.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:23358420" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020

	Serveur d'exploration sur la rapamycine et les champignons
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la rapamycine et les champignons

Large FK506-binding proteins shape the pharmacology of rapamycin.

Large FK506-binding proteins shape the pharmacology of rapamycin.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki